Roth Capital Starts Nektar Therapeutics (NKTR) at Buy
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $1.38 -2.82%
Rating Summary:
13 Buy, 10 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
13 Buy, 10 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
Roth Capital initiates coverage on Nektar Therapeutics (NASDAQ: NKTR) with a Buy. PT $10.00.
For an analyst ratings summary and ratings history on Nektar Therapeutics click here. For more ratings news on Nektar Therapeutics click here.
Shares of Nektar Therapeutics closed at $6.97 yesterday.
For an analyst ratings summary and ratings history on Nektar Therapeutics click here. For more ratings news on Nektar Therapeutics click here.
Shares of Nektar Therapeutics closed at $6.97 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'
- JPMorgan Starts Accent Group Ltd. (AX1:AU) at Overweight
- Singular Research Starts Citizens Inc. (CIA) at Buy-Long Term, 'Proven Distribution Growth'
Create E-mail Alert Related Categories
New CoverageRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
